TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07399067: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof-of-Concept Study to Evaluate the Efficacy and Safety of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 120 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,256,000

Rescue Site Savings

+$5,443,800

Unlock Full NCT07399067 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07399067 Rescue Dossier →